During the last session, Fulcrum Therapeutics Inc (NASDAQ:FULC)’s traded shares were 0.58 million, with the beta value of the company hitting 2.24. At the end of the trading day, the stock’s price was $8.86, reflecting an intraday loss of -1.01% or -$0.09. The 52-week high for the FULC share is $13.70, that puts it down -54.63 from that peak though still a striking 64.56% gain since the share price plummeted to a 52-week low of $3.14. The company’s market capitalization is $552.86M, and the average intraday trading volume over the past 10 days was 0.97 million shares, and the average trade volume was 888.03K shares over the past three months.
Fulcrum Therapeutics Inc (FULC) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.33. FULC has a Sell rating from 0 analyst(s) out of 13 analysts who have looked at this stock. 4 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 9 recommend a Buy rating for it.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Fulcrum Therapeutics Inc (NASDAQ:FULC) trade information
Fulcrum Therapeutics Inc (FULC) registered a -1.01% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.01% in intraday trading to $8.86, hitting a weekly high. The stock’s 5-day price performance is -7.23%, and it has moved by 13.59% in 30 days. Based on these gigs, the overall price performance for the year is 123.17%. The short interest in Fulcrum Therapeutics Inc (NASDAQ:FULC) is 7.26 million shares and it means that shorts have 5.31 day(s) to cover.
The consensus price target of analysts on Wall Street is $18, which implies an increase of 50.78% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $14 and $23 respectively. As a result, FULC is trading at a discount of -159.59% off the target high and -58.01% off the low.
Fulcrum Therapeutics Inc (FULC) estimates and forecasts
Statistics show that Fulcrum Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Fulcrum Therapeutics Inc (FULC) shares have gone up 8.71% during the last six months, with a year-to-date growth rate more than the industry average at 69.81% against 16.60.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 1.09%. While earnings are projected to return 76.19% in 2024, the next five years will return 16.40% per annum.
Fulcrum Therapeutics Inc (NASDAQ:FULC)’s Major holders
Fulcrum Therapeutics Inc insiders own 1.38% of total outstanding shares while institutional holders control 97.55%, with the float percentage being 98.91%. RA CAPITAL MANAGEMENT, L.P. is the largest shareholder of the company, while 155.0 institutions own stock in it. As of 2024-03-31, the company held over 11.61 million shares (or 18.9361% of all shares), a total value of $109.6 million in shares.
The next largest institutional holding, with 5.85 million shares, is of RTW INVESTMENTS, LP’s that is approximately 9.5351% of outstanding shares. At the market price on 2024-03-31, these shares were valued at $55.19 million.
